Beryl Drugs LimitedBSE: BERLDRG

Beryl Drugs Limited Press Release Apr 08 2026

· Issued by Beryl Drugs Limited via BSE India

Filed with BSE · · 1 page · English

Release

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No.ParticularsDetails
1Name of CompanyBeryl Drugs Ltd
2CIN NO.L02423MP1993PLC007840
3Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)2.39
4Highest Credit Rating during the previous FYNA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No
Name of the Company Secretary: KAMLESH GUPTA
Designation: COMPANY SECRETARY
EmailId: [email protected]
Name of the Chief Financial Officer: ASHISH BARASKAR
Designation: CFO
EmailId: [email protected]

Date: 08/04/2026

Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Beryl Drugs Limited on 6ix

Earlier from Beryl Drugs

Later from Beryl Drugs

All Beryl Drugs news releases